Introduction
In Japan, the development of ventricular assist devices (VADs) began in the 1960s [1, 2] , but the preliminary models were only used for post-operative cardiac failure [3] . In those terms, VADs were not used as a ''bridge to recovery (BTR),'' but as a temporary measure for self-recovery of the heart [4] [5] [6] . It was not intended for long-term care for chronic heart failure caused by cardiomyopathy. Recently, the connotation of BTR has significantly changed [7] [8] [9] , as it now refers to the recovery of the heart through various means of treatment, incorporating surgery [10, 11] , medicine [12] [13] [14] , cardiac resynchronization therapy [15] [16] [17] [18] , apheresis [19] , and regenerative medicine [20, 17, 21] , and not just the use of VADs.
On the other end of the spectrum, the artificial heart project that started in the USA during the 1960s aimed to make a replaceable and implantable ventricular device that would be the ultimate alternative to heart transplantation [22] . Because of this prestigious objective, it took nearly 30 years until the completion of AbioCor in 2000 (Abiomed, Danvers, MA, USA) ( Fig. 1) [23] . However, in the realm of long-term versatility, it is still far from perfection. Although the term ''destination therapy (DT)'' insinuates an impeccable alternative to heart transplantation, because of the limits to long-term use at this time, it refers to the care of elderly or unfit patients that are not reasonable candidates for transplant [24] . However, if mechanical heart treatment can surpass the 10-year survival rate for heart transplantation, it is a reasonable vision that VADs will be the most common form of cardiac failure care, excluding the youth [25, 26] .
Artificial heart treatment in Japan
In Japan, VAD treatment started in 1980 at the Mitsui Hospital [3] as a remedy for postcardiotomy heart failure (PCHF) and by November 2009, there has been 1128 cases ( Fig. 2) [27] . The majority of those cases are extracorporeal VADs manufactured by the Japanese company, Nipro (Osaka, Japan) ( Fig. 3 ). The first reported case that a VAD was used as a bridge to transplantation (BTT) occurred in 1992 at the Saitama University Medical School and the Osaka University Hospital for a patient with dilated cardiomyopathy [a Nipro left (L)VAD was used]. The latter case is the first successful BTT, when a 16-year-old male patient went from the University of Osaka to Texas in the USA and endured a 150-day bridge period. After the 1997 establishment of the Organ Transplantation Law, heart transplantation also started, with the first case occurring in 1999 at the University of Osaka. By July 2010 before the revision of the Organ Transplantation Law, there were only 69 heart transplants.
Unfortunately, because the number of donors is severely limited, almost 90% of patients resort to VADs as a BTT and the average bridge period surpasses 800 days. Due to this fact, the use of implantable VADs with minimal complications is imperative. However, only about 20% of VAD patients survive the bridge period, and patients who continue to wait for donors are in virtually the same situation as having received DT, even if the initial purpose was a BTT. A majority of patients with extracorporeal VADs require hospitalization, which still constitutes DT, but with a tremendously low quality of life (QOL). Furthermore, many cardiologists are still uneasy about DT for patients who are not eligible for transplantation [28, 29] . On the bright side, the successful implementation of implantable LVADs will allow patients to return home and work, raising the QOL. Branching from this, patients may be able to seek high quality DT as an alternative to transplantation in the near future. 
Implantable VAD use in destination therapy
In recent years, many Japanese academic conferences disputed the meaning of DT with the use of implantable LVADs. In 2008, the definition, ''long-term home treatment,'' was proposed and it has been generally accepted ever since [30] . In the past many total artificial hearts (TAH), such as the 1980 Jarvik 7 [31] and the 2001 AbioCor, underwent clinical trials [32] but none were able to achieve success in DT. Rather in the past 10 years, the use of implantable LVADs in DT for patients not eligible for heart transplants dramatically increased. In the 2001 HeartMate VE REMATCH study (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) [33] , the results showed that HeartMate VE LVAD treatment excelled over internal therapy. In 2002, the US Food and Drug Administration (FDA) approved the HeartMate VE for DT. Furthermore, in 2005, the HeartMate XVE study showed similar results, which certified increasing DT records ( Fig. 6 ). In the USA, the HeartMate II underwent clinical trials for DT and produced considerably enhanced records when compared to the HeartMate XVE. The American Heart Association (AHA) presented these records in 2009 [34] . As a result, the FDA approved the HeartMate II for DT in January 2010.
The use of destination therapy
Today's VAD treatment, like post-operative complications, can generally be broken down into two categories: use in acute cardiac failure, such as acute myocardial infarction or fulminant myocarditis, and use in chronic heart failure, such as dilated or ischemic cardiomyopathy. However, the line of distinction is unclear and is becoming more and more perplexing. That is to say, if a patient is diagnosed with acute cardiac failure and requires a VAD, he or she has three options: (1) Wait for a heart transplant (BTT); (2) Resort to long-term VAD use as a means to DT; and (3) Use with medicinal treatment or cardiac resynchronization therapy (CRT) as means of BTR aiming at recovery of patients' cardiac function. However, these same options exist for patients with chronic heart failure ( Fig. 7) . Certainly, in a donorlacking country like Japan, patients anticipating a BTT may end up receiving DT instead. Likewise, a patient hoping for a BTT may ultimately achieve a BTR by self-rehabilitation. Japan also has a long average wait period for donor hearts, ranging from 2 to 3 years. Therefore, BTT cases require at least a 2-year VAD treatment. In other words, VAD treatment as a BTT in Japan requires as much durability as a DT device used in the USA. Also, because Japan's current limit heart transplants to the age of 59 years and under, patients who can potentially receive BTT treatment in western countries can only receive DT in Japan. Unfortunately, the lack of Japanese evidence showing LVAD DT predominance over internal therapy makes it difficult for patients to receive financial reimbursement. In Japan, circulatory internal therapy has many ways of treatment, including CRTdefibrillator, intra-aortic balloon pump, or percutaneous cardiopulmonary support. Because of this, VADs were only used for patients with Stage D cardiac failure (Table 1) . It was considered to be a final procedure rather than a routine one. Therefore, the reality is that there is little data that accurately VAD records. However, using a VAD for patients with Stage D cardiac failure makes a bias point on the records because the chances of recovery are slim. Recently in western nations, a bridge to decision (placing a temporary VAD in a patient and waiting for recovery until further action) has become increasingly popular [35, 36] due to its financial affordability.
LVAD destination therapy and future prospects
In November 2009, the AHA presented the results of the HeartMate II Destination Therapy Trial. This trial consisted of data contrasting the first-generation pulsatile pump Heart-Mate XVE (PF VAD) and the second generation, continuous flow HeartMate II (CF VAD) [34] . The HeartMate II pump was roughly 1/5 the size and 1/3.5 the weight of the Heart-Mate XVE. It allowed easier implantation for use on smaller patients. Most importantly, this trial showed the HeartMate II's superiority over the predecessor in terms of 2-year survival rate. The HeartMate II managed a 46% (62/134) survival rate at 24 months, free from disabling stroke or re-operation for device replacement (intention-to-treat) versus an 11% (7/66) rate for the HeartMate XVE. Because the 134 patients with the HeartMate II were all in critical condition, either due to their age, body mass, diabetes, high blood pressure, renal failure, or recent migrant tumors, the 46% survival rate free from major complications was extraordinary. The average age of these patients was 62-63 years old and over
Figure 7
The target of treatment by implantable left ventricular assist device (LVAD) is to control heart failure at home and regain social activities for a patient who is depending on cathecholamine in hospital. The goal of implantable LVAD therapy can be heart transplant (BTT), recovery of the function of native heart (BTR), or life-prolonging treatment (DT, destination therapy). In Japan the heart transplant is restricted extremely, and we should consider it to be second guessing whether the goal is BTT, BTR, or DT. CRT, cardiac resynchronization therapy.
2/3 had ischemic cardiomyopathy with 20% experiencing brain complications. The studies on post-operative complications also showed that many suffered renal failure, pump exchanges, infections, cardiac arrhythmia, and breathing problems ( Fig. 8) . Perhaps above all, the pump complications 1-2 years after implantation, HeartMate XVE's largest drawback, dropped sharply (0.06/year vs. 0.51/year), and HeartMate II's pump exchange rate decreased to 6 cases out of every 100 VADs. In January 2010, the HeartMate II was Figure 6 Survival curve reported in REMATCH study (Heart Mate XVE Destination Therapy Trial) and Heart Mate II Destination Therapy Trial. HeartMate II showed significant higher survival rate at two years over HeartMate XVE [35, 36] . approved for DT use, and due to this, it is thought that DT will improve drastically.
Complications with LVAD destination therapy and the trend in the USA
Due to the expensive price, VADs in the USA can cost over $150,000 including the surgery fee, the use of LVADs for DT has been strictly controlled. In the early periods of LVADs, the hospital and insurance company had contracts that were in favor of the insurance company. Therefore, hospitals had to be prepared for a fairly large financial loss when they installed LVADs [37, 38] . In Japan, Novacor (Rueil-Malmaison, France) was approved by insurance agencies as BTT appropriate in 2004. However, due to the fact that the old model was approved and cost a large sum to exchange batteries, the manufacturer could not maintain use of the
Figure 8
Comparison of two-year event-free survival rate (free from death, disabling stroke, or re-operation for device replacement) between CF LVAD and PF LVAD. Significant superiority of CF LVAD in two-year event-free survival rate (46% vs. 11%) [36] . CF, continuous flow; LVAD, left ventricular assist device; PF, pulsatile flow.
product and dropped out of the competitive market in 2 years. Japanese academic societies have repeatedly asked for insurance reimbursements for device maintenance past 91 days for implantable LVADs. This time, in regards to the EVAHEART and DuraHeart VADs' manufacturers' approval and insurance reimbursements, the academic society's main concern is that those new regulations do not shape the Japanese market for implantable LVADs [39] . Without a structured market, implantable LVADs will disappear, much like the Novacor VAD. Furthermore, patients waiting for donor hearts will be forced to have extracorporeal VADs and hospitalization. Hospitals will also suffer because patients who stay for an extended period of time do not increase profits. Extended stay also points to the unsolved problem of hospital room overcapacity. The current revision provides reimbursement for pump device of 18,100,000-yen, and for over 91 days and a monthly 245,000-yen; however, even with this revision BTT cost for 3 years can be reduced about 49% with CF LVAD from that with Nipro VAD [40] . From now on, many experts anticipate that manufacturers will not experience a deficit and a structured market will soon appear.
On the other hand, the implantable VADs for DT (2002) were approved by the US Centers for Medicare and Medicaid Services (CMS) and the annual reimbursement levels increased considerably from $40,000 and under to $196,000 in 2009 ( Fig. 9) . Especially, the HeartMate II implantation surgery at teaching hospitals received $290,000, which indicates ''high quality medical care'' for that medical institution.
Clinical effectiveness and medical costs should correlate with one another in a capitalistic economy through market theory. By initiating that correlation, the competitive race to manufacture high quality medical devices finally begins [41] [42] [43] . Also, this motivation for higher achievement is vital to Japan's medical device industry.
Conclusion
In Japan, the fact that an extracorporeal VAD developed 30 years ago that gained approval 30-day use and medical reimbursement for acute heart failure in 1994 which was not permitted for BTT use until 2006, being used as a 2-3 year BTT is complete nonsense. Not only does forcing long-term hospitalization during the bridge period significantly reduce patient QOL, but it also limits the hospital's profit due to the lack of open beds for new patients. Supporting hospitalization for over 20 patients with VADs is an extreme burden on the hospital and two-thirds of them are not able to receive a donor organ. In summary, the lack in quality and quantity of VADs has been solely caused by government administrations. In developed nations such as the USA, patients are allowed to recover at home as a BTT or DT. In contrast, the current regulation in Japan severely limits the number of VAD patients. Is this something that can be overlooked? As Japan attempts to provide everyone with fair medical care, in reality, the administration is restraining patients with 30-year-old VADs in hospitals until they either receive a donor heart or pass away. There is definitely a need to clearly say that something is wrong. The clinical trials for the 5 major implantable LVADs designated in 2007 are going smoothly. The first end point observation (6 months after implantation) has been completed and the HeartMate XVE was approved in November 2009, the Dura-Heart and EVAHEART in December 2010; Jarvik 2000 and the HeartMate II are pending approval. In contrast, the regulations for heart transplants are more than 10 years behind.
The new organ transplant law passed in July 2009. There is much anticipation that this new law will carve the way for pediatric organ transplants. Since minors have a high demand for long-term LVADs due to the extended bridge period, new, improved VADs are needed more than they ever were.
